Preliminary Data on Post Market Safety Profiles of COVID 19 Vaccines in Rheumatic Diseases: Assessments on Various Vaccines in Use, Different Rheumatic Disease Subtypes, and Immunosuppressive Therapies: A Two-Centers StudyArticle Published on 2021-07-022022-10-28 Journal: Vaccines [Category] COVID-19, [키워드] adverse event AEs anti-COVID-19 vaccine approved assessment Biologic drugs clinician Comirnaty Complete COVID 19 COVID-19 vaccination COVID-19 vaccine demographic characteristics disease Disease activity DMARDs Efficacy evidenced fatigue Fever first dose flare headache Immunosuppressive agents immunosuppressive therapy increased risk Inflammatory information injection Italy myalgia older patient Pain participant Patient patients profile Relapse reported Rheumatic diseases risk Safe Safety safety profile SARS-CoV-2 second dose Severe infection vaccination Vaccinations Vaccine Vaxzevria were recorded [DOI] 10.3390/vaccines9070730 PMC 바로가기 [Article Type] Article
Efficacy of hepatitis B vaccination in children with rheumatic diseasesArticle Published on 2021-07-012023-06-11 Journal: Pediatrics international : official journal of the [Category] B형 간염, [키워드] children Hepatitis B virus immunosuppressive therapy rheumatic disease vaccination [DOI] 10.1111/ped.14533
Updates on management strategies of hepatitis B virus reactivation in patients with resolved hepatitis virus B infection undergoing immunosuppressive therapy in rheumatology and the current situation in Niigata Rheumatic CenterReview Published on 2021-07-012023-06-13 Journal: Modern rheumatology [Category] B형 간염, [키워드] Hepatitis B virus immunosuppressive therapy Nucleic acid analog Reactivation resolved infection. [DOI] 10.1080/14397595.2020.1832731 [Article Type] Review
Comparison of Tenofovir Disoproxil Fumarate and Entecavir in the Prophylaxis of HBV ReactivationRandomized Controlled Trial Published on 2021-07-012023-06-13 Journal: Digestive diseases and sciences [Category] B형 간염, [키워드] entecavir hepatitis B immunosuppressive therapy Prophylaxis Reactivation tenofovir [DOI] 10.1007/s10620-020-06506-w [Article Type] Randomized Controlled Trial
Kidney Transplantation and COVID-19: Two Case Reports신장 이식과 COVID-19: 2건의 사례 보고Case Reports Published on 2021-05-012022-09-11 Journal: Transplantation proceedings [Category] SARS, 치료제, [키워드] Azithromycin Blood level Comorbidities coronavirus disease Coronavirus disease 2019 Course COVID-19 COVID-19 pneumonia decreased mortality diagnosis of COVID-19 died dosage dose Favipiravir glucocorticoid Glucocorticoids hospital Hydroxychloroquine Immunosuppression immunosuppressive immunosuppressive therapy kidney transplant recipient kidney transplant recipients medication Methylprednisolone MMF mycophenolate mycophenolate mofetil oseltamivir Patient Pneumonia Population Prednisone reduction in reflect report risk tacrolimus therapeutic therapy Transplant transplantation treated Treatment treatment regimen treatment with methylprednisolone Trough level was reduced with COVID-19 [DOI] 10.1016/j.transproceed.2020.10.051 PMC 바로가기 [Article Type] Case Reports
A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trialSARS-CoV-2 백신(비활성화, Vero 세포)의 효능과 안전성을 평가하기 위한 무작위 이중 맹검 위약 대조 임상 3상 시험: 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약Letter Published on 2021-04-132022-09-10 Journal: Trials [Category] MERS, SARS, 비임상, 임상, 치료기술, [키워드] 1:1 24 hour 24 hours 95% confidence interval Activation Active surveillance administration Administrative Personnel Adverse adverse event adverse events Adverse reaction Adverse reactions African green monkey age Algorithm Aluminium aluminium hydroxide anaphylaxis Antibody test Antibody titer Antigen Arm asplenia assigned assumed assumption Autoimmune baseline bleeding disorders Blinding blood product blood products blood sample Blood samples breastfeeding women breath carried Cell culture China chloride Clinical efficacy clinical trial code Cohort cohorts comparator consent form cooperation Corticosteroid Corticosteroids COVID-19 COVID-19 cases COVID-19 disease COVID-19 symptoms COVID-19 test criteria Critical CRO Data and Safety Monitoring Board Day development diary dihydrogen DIHYDROGEN PHOSPHATE disease disodium disodium hydrogen phosphate dissemination dose dose of vaccination double blind double-blind double-blind study Efficacy Efficacy and safety element eligible Endpoint enrolled enrolment ethics committee evaluate event excluded exclusion criteria expected Follow-up follow-up period Frequency Gender genders green monkey group groups healthcare Healthcare professional healthcare professionals higher risk HIV infection hospital Hospitalization hydrogen Hydrogen phosphate hydroxide hypersensitivity identity IgG level IgG levels IgG test immunogenicity Immunoglobulin immunoglobulins immunosuppressive immunosuppressive therapy inactivated Inactivated Vaccines incidence incidence rate include Inclusion individual information informed consent form initiated Interactive Web Response System intramuscular dose investigator IWRS IWRS system kidney knowledge Local local reactions management medical doctors medical emergency Ministry of Health mortality rates neutralizing antibody Neutralizing antibody titer Novel coronavirus number Nurses objective Omega Other participant PCR PCR positivity performed Phase III Clinical Trial phosphate Placebo placebo group placebo-controlled positive pregnancy test pregnant preparation primary efficacy endpoint professional proportion protocol randomised randomised controlled trial randomised placebo controlled trial randomization Randomized Randomly Reactions receive recorded regimens Registration reported response risk risk of infection RT-PCR RT-PCR test RT-PCR tests Safety Monitoring Board Sample size SARS-CoV-2 vaccine SARS-CoV-2 virus screened second dose secondary Secondary objectives Serious Adverse Event Serious Adverse Events seroconversion rate Seropositivity severity severity of COVID-19 shown Sinovac sodium Sodium chloride sodium dihydrogen phosphate Sponsor status study group Study protocol subject subject’ supplementary material Symptom symptomatic symptomatic case symptomatic cases System systemic adverse reaction the ethics committee the timing the vaccine therapy Treatment treatment arm Trial Turkey two-sided vaccinated groups vaccination Vaccine Vero Vero Cell Web website width with COVID-19 within 6 months [DOI] 10.1186/s13063-021-05180-1 PMC 바로가기 [Article Type] Letter
Current Immunological and Clinical Perspective on Vaccinations in Multiple Sclerosis Patients: Are They Safe after All?Review Published on 2021-04-082022-10-29 Journal: International Journal of Molecular Sciences [Category] COVID-19, MERS, [키워드] approval Autoimmunity Bacillus benefit clinical coronavirus disease COVID-19 COVID-19 vaccination current disease disease modifying therapy (DMT) Efficacy Fever hepatitis B human papillomavirus immune system immunology Immunopathogenesis immunosuppressive therapy implication induce Influenza manuscript Multiple Multiple sclerosis (MS) mumps no correlation Pathogens Patient patients populations Protective raised Research risk Safety sclerosis susceptible treated Tuberculosis vaccination vaccination immunology Vaccine varicella [DOI] 10.3390/ijms22083859 PMC 바로가기 [Article Type] Review
Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure and function: a structured summary of a study protocol for a randomized controlled study입원하지 않은 경증에서 중등도의 COVID-19 환자에서 장내 미생물군유전체 조절의 자연사 및 영향을 평가하기 위한 가상화된 임상 연구 장내 미생물군 구조에 대한 KB109의 생리학적 효과를 평가하는 병렬 그룹 연구와 함께 무작위, 공개, 전향적 연구 및 기능: 무작위 대조 연구를 위한 연구 프로토콜의 구조화된 요약Letter Published on 2021-04-022022-09-10 Journal: Trials [Category] MERS, SARS, 임상, [키워드] 1:1 24 hours Ability absence addition adhere Affect age Ageusia allergy analysed Anosmia Anosmia/ageusia Antacid Antibiotics Antiviral assessment assigned Autoimmune disease Bariatric surgery baseline bilevel positive airway pressure Biomarker Biomarkers biomarkers of inflammation BiPAP Blinding blocker Blood blood sample Blood samples both groups bowel bowel resection breath Care care provider Cell change Chest chest tightness chills chronic lung disease cirrhosis clinical clinical study clinical trial Cold collected Community Comorbidity comparator Patients completion Compliance component computer Concomitant medication concomitant medications concurrent condition conducted contraindications coronavirus disease Coronavirus disease 2019 cough COVID-19 COVID-19 in patient COVID-19 symptom COVID-19 symptoms COVID-19 testing COVID-19-related symptom COVID-19-related symptoms COVID-19–related symptom COVID-19–related symptoms CPAP Cytokines D-dimer daily dose Day defined diarrhea dissemination drug duration of symptom Effect element eligible Enrollment evaluate evaluate the effect evaluated exacerbated exclusion criteria exploratory fatigue fatty Fatty acid feasible Female patients Fever fiber Follow-up follow-up period following group Gut gut microbiome gut microbiome composition gut microbiota headache Health Health care Health Care Utilization Health status healthcare Histamine history hospital Hospital admission Hospital admissions Hospitalization Hospitalized hypoxia Identifier IgM/IgG Immunity immunomodulatory immunosuppressive immunosuppressive therapy in both group include Infection Inflammation Inflammatory biomarker Inflammatory bowel disease information Informed consent inhibitors intake Interaction investigational agent irritable bowel syndrome KB109 Laboratory laboratory measures lactating library life Liver disease Lung disease magnitude malignancy management measure Measures medication medications Medicine metabolite Microbiome microbiota Mild mild to moderate Mild to moderate COVID-19 mild to moderate disease moderate Moderate COVID-19 moderate disease modulate modulation muscle pain nasal congestion neutralization assays not limited nucleic acid number objective Open-label opinion other compound other compounds outcome outcome measure Outpatient outpatients oxygen oxygen saturation Oxygen therapy Pain parallel group participant Participation Patient patient population Period Physical examination positive airway pressure Positive test Potential pre-symptomatic pregnant Primary outcome progression proportion proportions Prospective Study PROTECT protocol protocols proton pump provided pulse Pulse oximeter Quality of life Quantitative question randomisation randomised randomised controlled study randomization Randomized randomized controlled study receive recruitment reduction Registered reported response resting position risk risk of infection Sample size screened selected self-care sensitivities Sequencing serological serology shaking short-chain fatty acids Shortness of breath Sleep sleep apnea Smartphone sore throat specific biomarker specific biomarkers Spread SSC Standard Stool stratified Study design Study protocol study visit supplementary material Swab Symptom symptomatic patient Symptomatic patients Symptoms syndrome Tablet TEAEs Telemedicine telephone temperature the patient The United States therapy time Tolerability Treatment treatment-emergent adverse event undergo United States unlikely Viral Viral load water website worsening [DOI] 10.1186/s13063-021-05157-0 PMC 바로가기 [Article Type] Letter
Voclosporin: First Approval보클로스포린: 최초 승인Review Published on 2021-04-012022-09-11 Journal: Drugs [Category] 신약개발, [키워드] approval calcineurin Combination coronavirus disease Coronavirus disease 2019 COVID-19 immunosuppressive immunosuppressive therapy inhibitor kidney transplant recipients LUPKYNIS lupus nephritis Novel coronavirus novel coronavirus disease positive result regimen therapy trials USA voclosporin [DOI] 10.1007/s40265-021-01488-z PMC 바로가기 [Article Type] Review
The Impact of COVID-19 on Patients With Neuromyelitis Optica Spectrum Disorder Beyond Infection RiskNeurology Published on 2021-03-222022-11-01 Journal: Frontiers in Neurology [Category] COVID-19, [키워드] addressed Administered carried change clinical Cohort coronavirus disease COVID-19 COVID-19 infection COVID-19 infections cross-sectional demographic characteristics diagnosed with COVID-19 Disease activity disorder disorders effective evaluated Frequency Immune cell Immune status Immunoglobulin Immunosuppressant Immunosuppression immunosuppressive therapy Impact Infection interruption investigated majority measure median multiple sclerosis Neuromyelitis NMOSD pandemic Patient patients pilot study preventive measure Protective questionnaire Registered Relapse risk risk of COVID-19 significantly significantly higher social distancing Spectrum therapy Treatment [DOI] 10.3389/fneur.2021.657037 PMC 바로가기 [Article Type] Neurology